Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemiaArturo Pereira, Juan Carlos Hernández‐Boluda, Eduardo Arellano‐Rodrigo et al.|Annals of Hematology|2015Cited by 54
CNL and aCML should be considered as a single entity based on molecular profiles and outcomesGonzalo Carreño‐Tarragona, Nicholas C.P. Cross, Srinivasan Narayanan et al.|Blood Advances|2023Cited by 32
Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyureaAlberto Álvarez‐Larrán, Marta Garrote, Francisca Ferrer‐Marín et al.|Cancer|2022Cited by 32
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of MyelofibrosisAdrián Mosquera-Orgueira, Manuel Pérez‐Encinas, Alberto Hernández‐Sánchez et al.|HemaSphere|2022Cited by 30
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of MyelofibrosisJuan Carlos Hernández‐Boluda, Irene Pastor‐Galán, Eduardo Arellano‐Rodrigo et al.|British Journal of Haematology|2022Cited by 16